Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions |
umls-concept:C0001175,
umls-concept:C0008947,
umls-concept:C0008976,
umls-concept:C0030705,
umls-concept:C0032305,
umls-concept:C0033126,
umls-concept:C0034656,
umls-concept:C0041044,
umls-concept:C0087111,
umls-concept:C0205082,
umls-concept:C0449435,
umls-concept:C0547040,
umls-concept:C0917591,
umls-concept:C1257890,
umls-concept:C1881878,
umls-concept:C2603343
|
pubmed:issue |
3
|
pubmed:dateCreated |
1998-12-8
|
pubmed:abstractText |
This double-blind, randomized, multicenter trial compared clindamycin/primaquine (Cm/Prq) with trimethoprim-sulfamethoxazole (TMP-SMZ) as therapy for AIDS-related Pneumocystis carinii pneumonia (PCP). Forty-five patients received clindamycin (450 mg four times daily [q.i.d.]) and primaquine (15 mg of base/d); 42 received TMP-SMZ (320 mg/1,600 mg q.i.d. if weight of > or = 60 kg or 240 mg/1,200 mg q.i.d. if weight of < 60 kg) plus placebo primaquine. Overall, the efficacy of Cm/Prq was similar to that of TMP-SMZ (success rate, 76% vs. 79%, respectively); Cm/Prq was associated with fewer adverse events (P = .04), less steroid use (P = .18), and more rashes (P = .07). These differences were even greater for patients with PaO2 of > 70 mm Hg (P = .02, P = .04, and P = .02, respectively). For patients with PaO2 of < or = 70 mm Hg (23 Cm/Prq recipients and 21 TMP-SMZ recipients), the efficacy of Cm/Prq was similar to that of TMP-SMZ (success rate, 74% vs. 76%, respectively); Cm/Prq was associated with similar adverse events (P = .57), steroid use (P = .74), and rashes (P = .78). This trial confirms that Cm/Prq is a reasonable alternative therapy for mild and moderately severe PCP.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Sep
|
pubmed:issn |
1058-4838
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
27
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
524-30
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:9770152-AIDS-Related Opportunistic Infections,
pubmed-meshheading:9770152-Adult,
pubmed-meshheading:9770152-Anti-Infective Agents,
pubmed-meshheading:9770152-Clindamycin,
pubmed-meshheading:9770152-Double-Blind Method,
pubmed-meshheading:9770152-Drug Therapy, Combination,
pubmed-meshheading:9770152-Female,
pubmed-meshheading:9770152-Humans,
pubmed-meshheading:9770152-Male,
pubmed-meshheading:9770152-Pneumonia, Pneumocystis,
pubmed-meshheading:9770152-Primaquine,
pubmed-meshheading:9770152-Prospective Studies,
pubmed-meshheading:9770152-Treatment Outcome,
pubmed-meshheading:9770152-Trimethoprim-Sulfamethoxazole Combination
|
pubmed:year |
1998
|
pubmed:articleTitle |
Clindamycin with primaquine vs. Trimethoprim-sulfamethoxazole therapy for mild and moderately severe Pneumocystis carinii pneumonia in patients with AIDS: a multicenter, double-blind, randomized trial (CTN 004). CTN-PCP Study Group.
|
pubmed:affiliation |
Department of Microbiology and Infectious Diseases, Centre Hospitalier de l'Université de Montréal, Quebec, Canada.
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study
|